|
Name |
Wakodecaline A
|
Molecular Formula | C25H37NO6 | |
IUPAC Name* |
(2R)-2-[[(2S,3R,3aS,5aR,7S,9aS,9bR)-3-[(E,3S)-3-hydroxybut-1-enyl]-4,7,9b-trimethyl-1-oxo-3,3a,5a,6,7,8,9,9a-octahydro-2H-cyclopenta[a]naphthalene-2-carbonyl]-methylamino]-3-hydroxypropanoic acid
|
|
SMILES |
C[C@H]1CC[C@H]2[C@H](C1)C=C([C@H]3[C@@]2(C(=O)[C@H]([C@@H]3/C=C/[C@H](C)O)C(=O)N(C)[C@H](CO)C(=O)O)C)C
|
|
InChI |
InChI=1S/C25H37NO6/c1-13-6-9-18-16(10-13)11-14(2)21-17(8-7-15(3)28)20(22(29)25(18,21)4)23(30)26(5)19(12-27)24(31)32/h7-8,11,13,15-21,27-28H,6,9-10,12H2,1-5H3,(H,31,32)/b8-7+/t13-,15-,16+,17-,18-,19+,20-,21+,25+/m0/s1
|
|
InChIKey |
JDXAKDFLLVKKOO-UDDRCHRDSA-N
|
|
Synonyms |
Wakodecaline A
|
|
CAS | NA | |
PubChem CID | 139589497 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 447.6 | ALogp: | 2.1 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 115.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 32 | QED Weighted: | 0.426 |
Caco-2 Permeability: | -5.78 | MDCK Permeability: | 0.00035547 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.989 |
Human Intestinal Absorption (HIA): | 0.945 | 20% Bioavailability (F20%): | 0.015 |
30% Bioavailability (F30%): | 0.034 |
Blood-Brain-Barrier Penetration (BBB): | 0.635 | Plasma Protein Binding (PPB): | 79.11% |
Volume Distribution (VD): | 0.408 | Fu: | 14.05% |
CYP1A2-inhibitor: | 0.014 | CYP1A2-substrate: | 0.204 |
CYP2C19-inhibitor: | 0.015 | CYP2C19-substrate: | 0.726 |
CYP2C9-inhibitor: | 0.004 | CYP2C9-substrate: | 0.208 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.099 |
CYP3A4-inhibitor: | 0.097 | CYP3A4-substrate: | 0.202 |
Clearance (CL): | 5.792 | Half-life (T1/2): | 0.881 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.411 |
Drug-inuced Liver Injury (DILI): | 0.935 | AMES Toxicity: | 0.002 |
Rat Oral Acute Toxicity: | 0.863 | Maximum Recommended Daily Dose: | 0.906 |
Skin Sensitization: | 0.279 | Carcinogencity: | 0.613 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.919 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003818 | 0.809 | D0E9KA | 0.275 | ||||
ENC005774 | 0.527 | D0O5FY | 0.262 | ||||
ENC004320 | 0.527 | D04SFH | 0.244 | ||||
ENC004321 | 0.527 | D0I5DS | 0.234 | ||||
ENC005775 | 0.448 | D08PIQ | 0.234 | ||||
ENC004322 | 0.448 | D0F1EX | 0.231 | ||||
ENC003021 | 0.416 | D03IKT | 0.231 | ||||
ENC004339 | 0.402 | D0X7XG | 0.227 | ||||
ENC005181 | 0.393 | D0I1LH | 0.227 | ||||
ENC005182 | 0.393 | D05ZTH | 0.227 |